Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Notice regarding partial amendment of the Articles of Incorporation
Announcement on Reduction in Amounts of Stated Capital and Capital Reserves and Appropriation of Other Capital Surplus
Notice Regarding the Variance between consolidated results and results of the previous year, non-consolidated results and results of the previous year
Notice Regarding the Recording of Non-Operating Expense (Foreign Exchange Loss)
Strategic Development Progress Update for MDL-101: Clinical Readiness Advancement and Program Optimization
2025 Fiscal Year End Business and Financial report
Consolidated Financial Results for the Fiscal Year Ended December 31, 2025 [Japanese GAAP]
Modalis Therapeutics, Last Fiscal Year's Net Income Loss Widens, Current period performance is undisclosed.
Modalis Announces Publication in Human Gene Therapy of Study Demonstrating Efficient LAMA1 Gene Activation for the Treatment of LAMA2-CMD
Notice regarding the issuance of new shares as post-delivery restricted-stock-based remuneration
Modalis Therapeutics, Jan-Sep (Cumulative 3Q) Net Income Loss Widens, Jul-Sep Net Income Loss Widens
Notice Regarding the Recording of Non-Operating Expense (Foreign Exchange Loss)
Financial Results for the Nine Months Ended September 30, 2025
Consolidated Financial Results for the Nine Months Ended September 30, 2025 [Japanese GAAP]
Notice Regarding Change of the Executive Officer
A Patent Grant for "Method for Treating Alzheimer’s Disease by Targeting the MAPT Gene"
Modalis Receives Japanese Patent for DUX4 Gene-Targeted Therapy for Facioscapulohumeral Muscular Dystrophy
Business Plans and Matters Related to High Growth Potential
Business and Financial report for Six Months Ended June 30, 2025
Notice Regarding the Recording of Non-Operating Expense (Foreign Exchange Loss)